Immediate hypersensitivity reactions following monovalent 2009 pandemic influenza A (H1N1) vaccines: Reports to VAERS

Halsey, Neal A.; Griffioen, Mari A.; Dreskin, Stephen C.; Dekker, Cornelia L.; Wood, Robert A.; Sharma, Devindra; Jones, James F.; LaRussa, Philip; Garner, Jenny; Berger, Melvin; Proveaux, Tina M.; Vellozzi, Claudia; Broder, Karen R.; Setse, Rosanna; Pahud, Barbara; Hrncir, David; Choi, Hojung; Sparks, Robert; Williams, Sarah E.; Engler, Renata J.M.; Gidudu, Jane; Baxter, Roger; Klein, Nicola P.; Edwards, Kathryn M.; Cano, Maria; Kelso, John M.

doi:10.1016/j.vaccine.2013.09.066

Cited by 58 publications

(49 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…According to the VAERS, this phenomenon was observed to increase when introducing papillomavirus vaccine, meningococcal B vaccine, and pertussis vaccine. Syncopes or collapses may be found at a frequency of around 1 % [19, 41]. Importantly, not only the syncope itself but secondary injuries such as skull fracture and cerebral hemorrhage are of major concern.…”

Section: Methods To Reduce Side Effectsmentioning

confidence: 99%

See 1 more Smart Citation

Vaccination in Elite Athletes

Гартнер

Meyer

2014

Sports Med

View full text Add to dashboard Cite

Public health vaccination guidelines cannot be easily transferred to elite athletes. An enhanced benefit from preventing even mild diseases is obvious but stronger interference from otherwise minor side effects has to be considered as well. Thus, special vaccination guidelines for adult elite athletes are required. In most of them, protection should be strived for against tetanus, diphtheria, pertussis, influenza, hepatitis A, hepatitis B, measles, mumps and varicella. When living or traveling to endemic areas, the athletes should be immune against tick-borne encephalitis, yellow fever, Japanese encephalitis, poliomyelitis, typhoid fever, and meningococcal disease. Vaccination against pneumococci and Haemophilus influenzae type b is only relevant in athletes with certain underlying disorders. Rubella and papillomavirus vaccination might be considered after an individual risk–benefit analysis. Other vaccinations such as cholera, rabies, herpes zoster, and Bacille Calmette–Guérin (BCG) cannot be universally recommended for athletes at present. Only for a very few diseases, a determination of antibody titers is reasonable to avoid unnecessary vaccinations or to control efficacy of an individual’s vaccination (especially for measles, mumps, rubella, varicella, hepatitis B and, partly, hepatitis A). Vaccinations should be scheduled in a way that possible side effects are least likely to occur in periods of competition. Typically, vaccinations are well tolerated by elite athletes, and resulting antibody titers are not different from the general population. Side effects might be reduced by an optimal selection of vaccines and an appropriate technique of administration. Very few discipline-specific considerations apply to an athlete’s vaccination schedule mainly from the competition and training pattern as well as from the typical geographical distribution of competitive sites.

show abstract

Section: Methods To Reduce Side Effectsmentioning

confidence: 99%

“…Severe acute allergic reactions rarely occur (~1:10 million doses for influenza vaccine or measles vaccine) and manifest immediately after vaccination (seconds to 1 h) [41, 42]. However, anaphylactoid reaction is more common (~1:100,000) [42].…”

Section: Principles Of Vaccination In Elite Athletesmentioning

confidence: 99%

Vaccination in Elite Athletes

Гартнер

Meyer

2014

Sports Med

View full text Add to dashboard Cite

show abstract

“…An analysis of reports to VAERS of reactions following the 2009 administration of the H1N1 monovalent influenza vaccine revealed an overall rate of 10.7 immediate hypersensitivity reactions per million vaccine doses distributed, with a 2-fold higher rate for live attenuated vaccine as compared to inactivated vaccine [ 61 ]. The rate of anaphylaxis was 0.8 per million doses, with no significant differences by type of vaccine or manufacturer.…”

Section: Allergic Reactions To Specific Vaccinesmentioning

confidence: 99%

“…Egg allergy was considered to be a contraindication to the administration of these vaccines for many years; however we now know that these patients can safely receive influenza vaccines (See previous section " Influenza vaccine ") [ 133 ]. The incidence of anaphylaxis after influenza vaccine is estimated to be about one per million doses [ 61 , 134 , 135 ]. However, the egg allergy status of the patients who have had such reactions is unknown and anaphylactic reactions are also reported after administration of egg-free influenza vaccine [ 136 ].…”

Section: Approach To the Patient With Possible Allergies To Foods Or mentioning

confidence: 99%

International Consensus (ICON): allergic reactions to vaccines

Dreskin

Halsey

Kelso

et al. 2016

World Allergy Organization Journal

Self Cite

162

146

View full text Add to dashboard Cite

BackgroundRoutine immunization, one of the most effective public health interventions, has effectively reduced death and morbidity due to a variety of infectious diseases. However, allergic reactions to vaccines occur very rarely and can be life threatening. Given the large numbers of vaccines administered worldwide, there is a need for an international consensus regarding the evaluation and management of allergic reactions to vaccines.MethodsFollowing a review of the literature, and with the active participation of representatives from the World Allergy Organization (WAO), the European Academy of Allergy and Clinical Immunology (EAACI), the American Academy of Allergy, Asthma, and Immunology (AAAAI), and the American College of Allergy, Asthma, and Immunology (ACAAI), the final committee was formed with the purpose of having members who represented a wide-range of countries, had previously worked on vaccine safety, and included both allergist/immunologists as well as vaccinologists.ResultsConsensus was reached on a variety of topics, including: definition of immediate allergic reactions, including anaphylaxis, approaches to distinguish association from causality, approaches to patients with a history of an allergic reaction to a previous vaccine, and approaches to patients with a history of an allergic reaction to components of vaccines.ConclusionsThis document provides comprehensive and internationally accepted guidelines and access to on-line documents to help practitioners around the world identify allergic reactions following immunization. It also provides a framework for the evaluation and further management of patients who present either following an allergic reaction to a vaccine or with a history of allergy to a component of vaccines.

show abstract

“…CISA was used to enhance vaccine safety monitoring during the 2009-2010 H1N1 influenza pandemic. 27,28 Ongoing CISA studies are evaluating the safety of Tdap in pregnant women 29 and the feasibility of text messaging to monitor pregnancy outcomes after inactivated influenza vaccine. 30…”

Section: Clinical Immunization Safety Assessment (Cisa) Projectmentioning

confidence: 99%

The Centers for Disease Control and Prevention's public health response to monitoring Tdap safety in pregnant women in the United States

Moro

McNeil

Sukumaran

et al. 2015

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

In 2010, in response to a widespread pertussis outbreak and neonatal deaths, California became the first state to recommend routine administration of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine during pregnancy. In 2011, the Advisory Committee on Immunization Practices (ACIP) followed with a similar recommendation for Tdap vaccination during pregnancy for previously unvaccinated women. In 2012, this recommendation was expanded to include Tdap vaccination of every pregnant woman during each pregnancy. These recommendations were based on urgent public health needs and available evidence on the safety of other inactivated vaccines during pregnancy. However, there were limited data on the safety of Tdap during pregnancy. In response to the new ACIP recommendations, the Centers for Disease Control and Prevention (CDC) implemented ongoing collaborative studies to evaluate whether vaccination with Tdap during pregnancy adversely affects the health of mothers and their offspring and provide the committee with regular updates. The current commentary describes the public health actions taken by CDC to respond to the ACIP recommendation to study and monitor the safety of Tdap vaccines in pregnant women and describes the current state of knowledge on the safety of Tdap vaccines in pregnant women. Data from the various monitoring activities support the safety of Tdap use during pregnancy.

show abstract

Immediate hypersensitivity reactions following monovalent 2009 pandemic influenza A (H1N1) vaccines: Reports to VAERS

Cited by 58 publications

References 24 publications

Vaccination in Elite Athletes

Vaccination in Elite Athletes

International Consensus (ICON): allergic reactions to vaccines

The Centers for Disease Control and Prevention's public health response to monitoring Tdap safety in pregnant women in the United States

Contact Info

Product

Resources

About